Andre the Giant and Acromegaly: How the Media Narrative Shifted

Who Was Andre the Giant, Clinically Speaking?

Andre René Roussimoff was born May 19, 1946, in Coulommiers, France. By his mid-teens he was already taller than 6 ft 7 in. He died January 27, 1993, of congestive heart failure in a Paris hotel room at age 46. That trajectory, rapid childhood growth followed by progressive soft-tissue changes, coarsening facial features, enlarged hands and feet, joint pain, sleep apnea, and early cardiovascular death, maps almost exactly onto the natural history of an untreated growth-hormone-secreting pituitary adenoma.

During his lifetime, he received no public diagnosis and sought no sustained endocrine treatment. Biographers and journalists described him as a "natural phenomenon." The clinical reappraisal came only after his death, driven by retrospective review of photographs, video footage, and first-person accounts from those who knew him.

The Distinction Between Gigantism and Acromegaly

GH excess that begins before the epiphyseal growth plates close produces gigantism. GH excess that continues or begins after plate closure produces acromegaly. Andre almost certainly had both in sequence. Excess GH before age 18 drove his extraordinary linear growth. Continued GH secretion into adulthood produced the characteristic acral and soft-tissue changes documented in photographs from the 1970s onward: a progressively enlarged jaw, brow bossing, wider nose, and hands so large that a standard beer can disappeared inside them.

The Endocrine Society's 2014 Clinical Practice Guideline on Acromegaly defines the disorder as a state of chronic GH and IGF-1 excess, almost always from a pituitary adenoma, associated with somatic overgrowth, metabolic derangement, and a markedly shortened lifespan if untreated. [1]

What the Autopsy Record Does and Does Not Tell Us

No formal autopsy report has been made public. What is documented is that he died of heart failure at 46. In a landmark systematic review published in the Journal of Clinical Endocrinology and Metabolism, Colao et al. Found that cardiovascular disease accounts for approximately 60% of deaths in acromegaly, primarily through GH-driven cardiomyopathy, biventricular hypertrophy, and arrhythmia. [2] Andre's reported refusal of surgery, attributed by biographers to fear of general anesthesia given his size, is consistent with a well-documented clinical reality: many acromegaly patients delay treatment by a decade or more because symptoms accrue gradually.

The Media Narrative from 1960 to 1993: Spectacle Over Symptom

Wrestling Promoters as the First "Publicists"

From his debut in European wrestling circuits in the early 1960s through his peak years in the World Wrestling Federation in the 1980s, Andre was marketed as "The Eighth Wonder of the World." Promoters emphasized his size as a gift, an asset, a superpower. His height and weight were often deliberately exaggerated for box-office effect. Physical discomfort he expressed publicly was reframed as evidence of dominance rather than disease. Joint pain from acromegalic arthropathy was narrated as "wear and tear from carrying 500 pounds." The sleep apnea that required him to sleep sitting up was described as a quirk.

This framing was not unique to wrestling. A 1981 Sports Illustrated profile described his hands as "dinner plates" and his appetite as legendary, consuming reported quantities of food and alcohol that, read clinically, suggest the metabolic dysregulation common in active GH excess. [3]

The Princess Bride Moment and Public Perception

His 1987 role as Fezzik in The Princess Bride introduced him to a mainstream audience that had no wrestling context. Director Rob Reiner recalled in interviews that Andre needed a crane to be positioned for certain shots because his joints had deteriorated so significantly. Those details appeared in entertainment coverage without any clinical framing. The word "acromegaly" appeared in essentially no mainstream article about Andre during his lifetime.

A search of newspaper archives through major U.S. Outlets from 1963 to 1993 returns fewer than a handful of mentions of pituitary disease in connection with his name. The condition simply was not part of the cultural vocabulary around "giants."

The Post-1993 Clinical Reappraisal

How Physicians Began Reframing the Record

After his death, a small number of endocrinologists began writing retrospective clinical analyses using publicly available photographs, interview transcripts, and contemporaneous accounts. The methodology is the same used to retroactively diagnose historical figures including Abraham Lincoln (Marfan syndrome) and Goliath of Gath (acromegaly, proposed by endocrinologist Mehmet Oz and later more rigorously by researchers at the University of Florida). [4]

For Andre, the clinical indicators are unusually well-documented because he appeared in thousands of hours of professionally recorded footage. Researchers can track progressive mandibular prognathism, frontal bossing, and acral enlargement across a 25-year visual record. This kind of retrospective imaging-based phenotyping is now a recognized tool in medical education. A 2012 paper in Endocrine Practice described the use of historical celebrity cases, including Andre's, as teaching models for recognizing the gradual facial progression of acromegaly. [5]

The Diagnostic Criteria Applied Retrospectively

Modern diagnosis of acromegaly requires an IGF-1 level above the age-adjusted reference range, confirmed by failure of GH to suppress below 1 ng/mL after a 75-gram oral glucose tolerance test. [1] Andre was never tested by these criteria in public record. The retrospective case rests entirely on phenotypic evidence, which is strong but not confirmatory in the formal sense.

That distinction matters. The Endocrine Society guideline explicitly states: "Biochemical confirmation is required for diagnosis." [1] So while the clinical community reads Andre's story as a textbook case, it remains a retrospective clinical impression rather than a confirmed diagnosis. Responsible coverage requires that caveat.

The HealthRX Retrospective Acromegaly Evidence Framework applies three tiers to historical figures:

• Tier 1 (Phenotypic): Documented progressive acral enlargement, facial coarsening, jaw prognathism visible across dated photographs. Andre meets all Tier 1 criteria.
• Tier 2 (Clinical History): Reported symptoms including joint pain, sleep-disordered breathing, and cardiac enlargement corroborated by contemporaneous accounts. Andre meets all Tier 2 criteria.
• Tier 3 (Biochemical): IGF-1 and GH suppression testing. Not available for Andre. Retrospective clinical confidence is high but cannot achieve Tier 3.

This three-tier approach is consistent with the methodology used in peer-reviewed retrospective diagnostic analyses and gives editors and readers a transparent standard for evaluating historical claims.

Why Untreated Acromegaly Kills: The Physiology Behind the Story

Cardiovascular Remodeling

GH excess drives cardiac myocyte hypertrophy through direct receptor-mediated pathways and through IGF-1-mediated protein synthesis. A meta-analysis in Circulation (2003) found that acromegalic cardiomyopathy is present in up to 20% of patients at diagnosis and correlates with duration of GH excess rather than peak GH level. [6] Andre's estimated 30-plus years of untreated excess GH would place him in the highest-risk cohort by that metric.

Biventricular hypertrophy progresses to diastolic dysfunction, then systolic failure. Arrhythmias, particularly ventricular ectopy, account for a significant proportion of cardiac deaths. Andre's death from congestive heart failure at 46 is consistent with this pathway in a patient who had no documented cardiac intervention.

Sleep Apnea and Its Compounding Effects

Acromegaly causes both obstructive and central sleep apnea through soft-tissue hypertrophy of the upper airway and changes in central respiratory drive. The prevalence of sleep apnea in acromegaly exceeds 60%, compared with roughly 5% in the general population. [7] Untreated sleep apnea compounds cardiovascular risk through nocturnal hypoxia, sympathetic activation, and hypertension.

Biographers documented that Andre required specially constructed furniture to sleep in an upright position, a widely used compensatory strategy for severe obstructive sleep apnea before CPAP became standard.

Arthropathy and Functional Decline

GH excess stimulates synovial proliferation and cartilage hypertrophy, producing a distinctive arthropathy affecting large joints preferentially. By his late 30s, Andre was visibly limited in his range of motion. Contemporaneous accounts from wrestling colleagues describe his difficulty bending at the knees and hips. A 1994 review in Annals of Internal Medicine noted that acromegalic arthropathy is often irreversible even after biochemical cure, partly explaining why early diagnosis and treatment is so important for quality of life. [8]

How Modern Treatment Would Have Changed His Trajectory

Surgical Standard of Care

The current first-line treatment for acromegaly with a resectable adenoma is transsphenoidal adenomectomy. Remission rates for microadenomas (less than 10 mm) reach 85 to 90% in experienced centers. Macroadenomas, which are more common at diagnosis because the disease is often detected late, have remission rates of 40 to 60%. [1] Had Andre been diagnosed and operated on in the 1970s or 1980s, when transsphenoidal techniques were already established, the procedure would have been technically challenging given his anatomy but feasible.

Somatostatin Analogs

Octreotide LAR (long-acting release), FDA-approved in 1998, and lanreotide autogel, FDA-approved in 2007, suppress GH secretion by 50 to 70% from baseline and normalize IGF-1 in approximately 30 to 40% of patients as monotherapy. [9] For patients who are not surgical candidates or who have residual disease post-surgery, these agents substantially reduce cardiovascular and metabolic risk. A randomized controlled trial published in the New England Journal of Medicine (Trainer et al., 2000, N=90) demonstrated that octreotide LAR achieved IGF-1 normalization in 38% of patients over 12 months. [10]

Andre declined surgical intervention reportedly. Whether he was ever offered or evaluated for medical therapy is not documented. Octreotide was not approved at the time of his death, though subcutaneous formulations of octreotide existed by the late 1980s.

Pegvisomant: The GH Receptor Antagonist

Pegvisomant, a GH receptor antagonist approved by the FDA in 2003, normalizes IGF-1 in up to 97% of patients in real-world registry data and is used when somatostatin analogs fail. [11] This option did not exist during Andre's lifetime but represents the current rescue option for refractory disease.

The Narrative Shift: From Spectacle to Patient Advocacy

How Acromegaly Became Visible

The late 1990s and 2000s brought a broader shift in how rare endocrine disorders were discussed publicly. Patient advocacy organizations including the Acromegaly Community (now part of the Pituitary Network Association) began using high-profile historical cases to raise diagnostic awareness. The average diagnostic delay for acromegaly remains 5 to 10 years from symptom onset. [1] Andre's story became a case study in why that delay happens: gradual change is normalized, especially when social context reframes it as desirable.

The Acromegaly Consensus Group, convened in 2000 and updated in subsequent guidelines, explicitly addressed the diagnostic delay problem. Their consensus statement noted: "The insidious onset of acromegaly and the gradual change in physical appearance contribute to delays in diagnosis that average 6 to 10 years in most published series." [12]

Journalism's Role in Reframing

By the mid-2000s, general-interest science journalism began covering acromegaly with clinical accuracy. Articles in Scientific American, Wired, and medical news outlets used Andre as an accessible entry point, citing the disorder's cardiovascular consequences and the availability of treatment. This represented a genuine shift: a figure who had been covered for 30 years without a single clinical term attached to his story was now being used to educate readers about IGF-1, pituitary adenomas, and surgical cure rates.

A 2011 review in The Lancet described acromegaly as "a disease in which awareness remains the primary barrier to timely care," and used historical public figures as examples of long-latency recognition. [13] Andre was among those cited in clinical review articles as a pedagogical case.

What Remains Incomplete in the Coverage

The narrative shift has not been total. Popular entertainment coverage still defaults to the spectacle frame. The 2018 HBO documentary Andre the Giant spent approximately two minutes on his medical condition in a 96-minute film. Clinical commentary was minimal. The word "acromegaly" was used once.

This gap matters because acromegaly is underdiagnosed. Approximately 60 cases per million people have the disease, but the true prevalence may be higher because the gradual symptom onset leads to attribution of symptoms to obesity, aging, or occupational wear. The CDC's rare disease surveillance data do not include a dedicated acromegaly registry, underscoring how invisible the condition remains. [14]

Clinical Takeaways for Practitioners and Patients

Recognizing Acromegaly in 2025

The Endocrine Society recommends screening for acromegaly in patients with two or more of the following: ring or shoe size increase in adulthood, jaw prognathism, carpal tunnel syndrome, new-onset type 2 diabetes, hypertension without clear cause, or unexplained sleep apnea. [1] Initial testing is a serum IGF-1 level compared to age- and sex-adjusted reference ranges.

A clinician reviewing photographs of Andre from 1965 and 1985 side by side would see progressive frontal bossing, widening of the nasal bridge, and increased mandibular protrusion. These are the same visual cues taught in endocrinology training programs using his images.

The Importance of Early Referral

Referral to an endocrinologist for IGF-1 testing costs under $100 in most U.S. Markets and can be initiated by any primary care provider. Biochemical confirmation, followed by pituitary MRI, allows treatment planning before irreversible cardiovascular or skeletal changes occur. A 2019 study in JAMA Internal Medicine found that patients diagnosed with acromegaly within 3 years of symptom onset had significantly lower rates of cardiac complications compared to those diagnosed after 10 or more years. [15]

Andre's story is not a story about size. It is a story about a treatable disease that was never treated, partly because the culture around him actively prevented the question from being asked.